星空体育官方入口网站网址大全-登录入口官网

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2024-06-23 ms5000002020096439 来自天津

original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？

40 0

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-12-28 1475f52dm25(暂无昵称) 来自广东省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。

74 0

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-04-21 summer月

审稿速度:1.0 | 投稿命中率:50.0
经验分享：审稿速度很快，4.1投稿，4.3拒稿

90 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-11-18 198366_2801

想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！

86 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-05-23 阿曾曾曾曾来自上海

回顾性文章收吗，自认为有点新意= =

87 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-09-10 小双子

偏重的研究方向：肿瘤
经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M

94 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-12-21 ms1859105519819171 来自天津

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：癌症
经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。
Decision on Manuscript ID CNCR-22-3013
19-Dec-2022
Dear Dr. ******,
Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer.

However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link.

CA: A Cancer Journal for Clinicians:

To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************

71 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-09-09 ms7000002132756283

请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊

115 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-04-07 赛华佗

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肺癌;癌症;肿瘤
经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了

103 0

[GetPortalCommentsPageByObjectIdResponse(id=2211236, encodeId=b8fb221123628, content=original article限制3500字吗，为什么我看有的已经发出来的文章都快4000字了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=117b9079198, createdName=ms5000002020096439, createdTime=Sun Jun 23 13:42:50 CST 2024, time=2024-06-23, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2177677, encodeId=a00521e7677ea, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：我选的泌尿生殖系肿瘤肿瘤栏目，编辑很友好，第二天还是第三天就under review了，小修两次。第一次小修2位审稿人提了意见，不是很难回答，实在有补充不了的内容委婉说明，再在limitation部分阐述出来。第二次小修是要求润色，我还是狠狠心用了Wiley出版社的润色，毕竟是人家CANCER杂志所在的出版社。从投稿到接收总共1.5个月左右。总的来说，还是推荐投稿试试，我是小癌种的回顾性研究，有点新意，编辑还是会考虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3c95211631, createdName=1475f52dm25(暂无昵称), createdTime=Thu Dec 28 08:59:23 CST 2023, time=2023-12-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1213206, encodeId=b72012132063e, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：审稿速度很快，4.1投稿，4.3拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e2a5469697, createdName=summer月, createdTime=Thu Apr 21 16:57:36 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2101232, encodeId=fd6b21012320d, content=想问问前辈们这个杂志最近审稿快不快，孩子快该毕业了，谢谢大家！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=92046435613, createdName=198366_2801, createdTime=Fri Nov 18 00:22:16 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138537, encodeId=43a6213853e21, content=回顾性文章收吗，自认为有点新意= =, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5c5d5201162, createdName=阿曾曾曾曾, createdTime=Tue May 23 09:47:20 CST 2023, time=2023-05-23, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1016258, encodeId=0c9f10162583b, content=偏重的研究方向：肿瘤 经验分享：想请问一下大家，我的figure用AI转成TIFF，提交之后不能在生成的PDF里显示，大家有解决方法吗？是文件太大了吗？15M, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02dd5501651, createdName=小双子, createdTime=Fri Sep 10 09:13:49 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106883, encodeId=ce68210688316, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：癌症 经验分享：投了3次都是desk rejection，真的很难啃，虽然影响因子不算高，但为何我的文章总是入不了编辑法眼，很是郁闷。最近这次拒稿，编辑竟然让我转投神刊CA: A Cancer Journal for Clinicians。CA的IF都286了，明摆着是大佬集中地，CANCER才6.9分，凭啥收你的破烂文章啊？我实在搞不懂编辑是不是在拿我开玩笑，不过他既然安排我一键转投，我也就确认了。坐等CA秒拒吧。 Decision on Manuscript ID CNCR-22-3013 19-Dec-2022 Dear Dr. ******, Thank you for your recent manuscript submission of "*******************" (CNCR-22-3013) to Cancer. Your paper has undergone initial review. Due to overall page constraints, only so many papers can be published, and your paper did not receive a high enough priority score for publication in Cancer. However, your paper is a candidate for transfer to another journal published by Wiley. Please consider the journal option below, and if you would like us to transfer your manuscript and associated reviews (if your paper received reviews), please click the first link. CA: A Cancer Journal for Clinicians: To ACCEPT and AUTOMATICALLY TRANSFER your paper and any related reviews: *** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. *** https://mc.manuscriptcentral.com/cancer?URL_MASK=bb5799***********************, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15a31892640, createdName=ms1859105519819171, createdTime=Wed Dec 21 09:09:48 CST 2022, time=2022-12-21, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=1016174, encodeId=096e10161e449, content=请问一下大家，这个杂志的格式要求在哪里看啊啊啊啊，找了半天没有找到模板，你们投稿的时候都是怎么改的格式啊啊啊啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6fe75529800, createdName=ms7000002132756283, createdTime=Thu Sep 09 22:39:57 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209303, encodeId=dfa912093038a, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;癌症;肿瘤 经验分享：现在名字相似的期刊太多了，如cancer, cancers, cancer j, 太混淆了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Thu Apr 07 17:55:51 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1105716, encodeId=f4061105e16f1, content=结构式和整段式摘要如何选择？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-27 MS54455111222

结构式和整段式摘要如何选择？

98 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务